Find out how researchers profile and identify molecular behaviors in advanced HER2+ tumors:
- Learn potential ways to identify molecular behaviors of advanced HER2+ metastatic breast cancer tumor samples
- Understand the complementary nature of dPCR and NGS liquid biopsy analysis
- Increase awareness of the comprehensive advantages of combined tissue biopsy and liquid biopsy analysis
Please fill out the short form to access the webinar and presentation.
Impact of liquid biopsy in advanced HER2+ breast cancer tumors: a follow-up study
AIRC post-doctoral fellow, Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute
Dr. Allegretti discusses his clinical research on HER2+ metastatic breast cancer samples using liquid biopsy analysis. This retrospective study aims to determine feasibility of profiling and tracking the molecular behavior of advanced HER2+ breast cancer tumors during drug treatments using liquid biopsy samples. Analysis is conducted using next-generation sequencing (NGS) and digital PCR (dPCR).
Learn more about Thermo Fisher Scientific’s liquid biopsy solutions:
Fill in the form to view the free on-demand webinar.